A cluster of anthracycline biosynthetic genes isolated from
INTRODUCTION
Anthracyclines, produced mainly by Streptomyes spp. , are aromatic polyketide antibiotics widely used in cancer chemotherapy. Nogalamycin is a member of an anthracycline group produced by Streptomyces nogalater (Bhuyan & Dietz, 1965; Wiley e t al., 1977; Wiley e t al., 1968) . Several derivatives of nogalamycin have been prepared and their pharmacological properties characterized (Li & Krueger, 1991) ; one of them, menogaril, is undergoing clinical trials for use in cancer chemotherapy. So far, studies of nogalamycin have been mainly concerned with the biological and chemical properties of the compound. N o biosynthetic studies have been described since Wiley etal. (1978) showed that acetate is the starting unit in the pathway.
We have previously reported a study on the biosynthetic pathway for aclacinomycins (Ylihonko e t al., 1994) . Aklavinone, the aglycone moiety of aclacinomycins, is a precursor of several natural anthracyclines (Oki e t al., 1975) . The aglycone of nogalamycin differs from aklavinone in having the opposite stereochemistry at position 9 (Fig. l) , and in the side chain, where a methyl group replaces an ethyl group. The C-9 side chains each derive from the starter unit for polyketide synthesis, which is an acetate in nogalamycin and a propionate in aklavinone Abbreviations: MPLC, medium pressure liquid chromatography; PKS, polyketide synthase; tsr, thiostrepton.
biosynthesis. Therefore, aklavinone is not a precursor of nogalamycin, but the steps in the biosynthetic pathway ( Fig. 1 ) are probably analogous.
In this paper, we describe the cloning and expression in Streptomyes lividans of a gene cluster from S. nogalater, which caused the production of a novel compound derived from nogalonic acid methyl ester, a proposed intermediate in the biosynthesis of nogalamycin. The gene cluster was implicated in nogalamycin biosynthesis by gene disruption and was further characterized by the complementation of Streptomyces galilaem mu tants blocked in the pathway for biosynthesis of aclacinomycins, the anthracyclines of wild-type S. galilaezis. Besides characterizing the gene cluster, this offered a way to produce hybrid antibiotics by the technique of Hopwood e t al.
(1 985b). The hybrid anthracyclines produced have auramycinone, with a methyl side chain at position 9 as in nogalamycin, as the aglycone moiety. The C-9 side chain of anthracyclines is derived from a biosynthetic starter unit selected by the polyketide synthase (PKS). Modification and glycosylation of the aglycone are, however, dependent on the host strains used. With this system it may be possible to produce a series of novel anthracyclines that can be screened for cytostatic activity.
METHODS
Bacterial strains, plasmids and culture conditions. The bacterial strains and plasmids used in this study are listed in (Ylihonko etal., 1994 were isolated and purified as described elsewhere .
Gene disruption. The 0.5 kb and 1.5 kb EcoRI-BamHI fragments from the act1-hybridizing region (Fig. 2) were cloned in the integration vector pGM160, and digested with EcoRI and BamHI. The resulting plasmids pGSnl and pGsn2, respectively, were introduced by transformation into S. lividans TK24 and recombinant clones were selected with thiostrepton (tsr). Plasmids were extracted from TK24 and introduced into S. nogalater. The transformants were transferred to plates of ISP4 agar containing tsr (50 pg ml-') for sporulation. The spores were used to inoculate TSB medium and cultures were grown at 39 OC, without selection pressure, to eliminate the autonomously replicating plasmids. Four-day-old TSB cultures were plated on ISP4 agar supplemented with tsr and resistant clones were assayed for nogalamycin production. This method allows selection of single crossover products only.
Subcloning in Streptomyces. Small DNA fragments from 3, clones were first cloned in E. coli XL1-Blue using pUC19. pIJ486 was used for all subclones in Streptomyces strains. Recombinant plasmids were introduced by transformation into S. lividans as described by Hopwood et al. (1985a) , and after isolation from S. lizjidans were transferred to S. galzlaezls. For transformations in S. galilaezts, the procedure for S. lividans was modified by using SGYEME instead of YEME (110 g Two HPLC systems were used to characterize the products and to determine the purity of MPLC (medium pressure liquid chromtography) fractions. Both systems used an octadecyl reverse phase column (RP-18). The solvent systems were acetonitrilelbuffer (7 : 3, v/v) (S-1) and acetonitrile/buffer/ methanol (5:3:2, by vol.) (S-2), the buffer being 60 mM potassium dihydrogen phosphate adjusted with citric acid to pH 3. The compounds were detected with a UV monitor at 254 nm.
Cosynthesis. Portions (1 ml) from each of two 48-h-old El cultures were used to inoculate 50 ml El medium in a 250 ml Erlenmeyer flask. The flasks were shaken (330 r.p.m.) at 28 O C . After incubation for 2-3 d the co-culture was assayed for anthracyclines by TLC.
Production of anthracycline metabolites. The compounds were produced in 7 1 fermenters containing 5.5 1 El medium supplemented with tsr (5 pg ml-'). The fermentation was carried out at 28 "C with aeration at 6 1 min-' and with stirring at 280 r.p.m. After 4-6 d, the broth was separated by centrifugation. Anthracyclines and their intermediates were extracted from the pellet with methanol. The methanol extract was added to the broth supernatant and the solution was extracted with chloroform. The chloroform extracts were evaporated, then resolubilized in a small amount of chloroform. The solution was chromatographed on a silica gel column with chloroform/acetic acid (200 : 1, v/v) (neutral intermediates and aglycones) and with gradients of chloroform/methanol/acetic acid (200 : 0 : 1 to 200 : 20 : 1, by vol.) (glycosides) using a MPLC system. Fractions containing pure compounds were combined and evaporated to dryness.
Spectroscopy. 'HNMR spectra were recorded with a Jeol JNM-GX400 system. The spectra were assigned by comparing them to those of aklavinone and aklavinone glycosides.
RESULTS
Isolation of act/-and acm-hybridizing DNA from S. nogalater act1 DNA, encoding the actinorhodin PIG (FernandezMoreno et al., 1992) , has been successfully used to identify the biosynthetic genes of different polyketide antibiotics (for example, Bibb etal., 1994; Sherman etal., 1989; Yu et al., 1994 
Disruption of a putative nogalamycin gene cluster
To implicate the cloned Sno cluster in nogalamycin biosynthesis, pGSnl and pGSn2 were constructed (Fig.  2) . pGSn2 consisted of almost the whole of ORFl and 300 bp of the upstream sequence, whilst the 0.5 kb insert of pGSnl contained 150 bp of the 3' end of ORFl and 350 bp of the 5' end of ORF2 (Fig. 2) Three of five pGSnl clones retained tsr resistance during cultivation and were analysed for nogalamycin production. Two were non-producing and the third produced a low yield of nogalamycin-related metabolites. Evidence for plasmid integration in the two non-producing clones was supported by Southern hybridization. Three of the five putative pGSn2 integrants produced nogalamycin at wild-type levels, and based on Southern hybridization, they still carried free plasmids; the other two putative integrants produced diminished amounts of nogalamycin. Overall, the results implicated the cloned Sno cluster in nogalamycin biosynthesis.
Subcloning of 1 clones in 5. lividans
Subcloning of the 6 kb EcoRI fragment from ;1 clone Sno3, and of the 12 kb BgAI fragment from Snol, into PI 5486 gave pSY6 and pSY 15, respectively (Fig. 2 ). pSY6 and pSY15 were then introduced by transformation into S. lividans TK24. Subcloning in pUC19 of the 2 kb fragment excised from Snol with EcoRI gave pSnl. This plasmid was extracted from E . coli, and the insert was ligated into pIJ486 and introduced into TK24 to give Cloning of nogalamycin biosynthetic genes $ The structures of compounds I, 111, IV and V are shown in Fig. 3 pSY 1. A restriction map of the A clones with the fragments used for subcloning is shown in Fig. 2. S. liiiidans does not produce anthracyclines and is typically colourless or blue on ISP4 agar, but S. lividans TK24 carrying pSYl5 differed from the parent strain in giving a brown colour on ISP4 agar. When cultured in the anthracycline production medium E l , TK24 did not produce any coloured compounds, but yellow and red compounds were detected in a sample from the TK24(pSY15) culture. The properties of the main products of TK24(pSY15) are shown in Table 2 . One of the products (I, Fig. 1 ) was determined by NMR spectroscopy (Table 3) to be a novel compound by comparing the spectrum with those of aklavinone and auramycinone. The aromatic portion of this compound is the same as the aromatic portion of the two aglycones. The fourth ring is not condensed, since the integral of the singlet corresponding to C-10 in the aglycone gives two protons instead of one. The position corresponding to C-9 carries a proton because the methyl at position 13 gives a doublet instead of a singlet. Compound I is suggested to be a shunt product derived from nogalonic acid methyl ester, a hypothetical intermediate of nogalamycin biosynthesis similar to the aclacinomycin precursor, aklanonic acid methyl ester (Ylihonko e t al., 1994) . pSY6, which lacks the actl-hybridizing region, did not cause production of anthracyclines or their intermediates in S. lividans. Also, pSY 1, containing the actl-hybridizing part of pSY 15, failed to cause production of anthracycline metabolites in El medium.
Cosynt hesis
Structural analysis of compounds produced by S. lividans TK24(pSY15) suggested that the 12 kb BglII fragment from S. nogalater encodes several enzymes for anthracycline biosynthesis. To test this, TK24(pSY 15) was cocultured with S. nogalater Sno366 (L. Cong, K. Ylihonko & P. Mantsala, unpublished results). The latter strain failed to produce any coloured compound in El medium, and was characterized as a mutant blocked early in the nogalamycin pathway. The co-cultures produced nogalamycin, thus suggesting that the compounds are probably derived from the nogalamycin pathway because they were converted to this product by Sno366.
Complementation of S. galilaeus mutant H028 and production of hybrid anthracyclines
S. galilaezts ATCC 31 61 5 produces aclacinomycins, which consist of aklavinone and a sugar moiety (rhodosamine-2-deoxyfucose-cinerulose) attached to C-7 (Fujiwara e t al., 1980) . S. galilaew mutant H028 (Ylihonko e t al., 1994) , which does not produce any anthracycline metabolites, was transformed with pSY 15. The transformants were cultured in El medium and their products were first characterized by TLC and HPLC. The properties of the products from H028(pSY15) are shown in Table 2 . The structures of the aglycone and two glycosides were then determined by 'HNMR spectroscopy (Table 3 ). The main compound of H028(pSY 15) was aglycone I11 (auramycinone) which was also the aglycone moiety in the glycoside fraction. Auramycin-like hybrid glycosides were determined to be compounds IV (auramycinonerhodosamine-deoxyfucose) and V (auramycinonerhodinose-deoxyfucose) (Fig. 1) by comparing their NMR spectra with that of aclacinomycin S (aklavinone diglycoside). The spectrum of IV was nearly identical to this compound, except that the side chain at C-9 gave a singlet for a methyl group instead of the ethyl group of aklavinone. Compound V lacked, additionally, the dimethylamine group and gave two double triplets of rhodinose 2',3'. Compound IV has earlier been reported as a * AcmS, aklavinone-rhodosarnine-deoxyfucose. mutant product (Hoshino et al., 1982) . Compound V, auramycinone with neutral glycosides, is a novel compound similar to an aklavinone glycoside isolated earlier from H054, a mutant of S. galilaezzs defective in glycosylation (Ylihonko e t d., 1994) .
DISCUSSION
To establish that we had cloned the biosynthetic genes for nogalamycin we determined their function by gene disruption. Putative enzymes for biosynthesis of anthracyclines were deduced from the structure of a compound produced by heterologous expression. In addition, we demonstrated that it is possible to use the genes as a cluster when constructing strains to produce hybrid an thrac yclines.
Because of the restriction barriers in S. galilaezu Cloning of nogalamycin biosynthetic genes genes for actinorhodin, although it is possible that they also take part in the biosynthesis of tricyclic compounds. Bartel et al. (1 990) have complemented a PKS-deficient S. galilaeus mutant with a gene for actinorhodin but this gene product acts in the early stage of biosynthesis using the polyketide backbone as a substrate. However, an aromatase and a cyclase for actinorhodin do not accept carbon chains longer than 16 as substrates (McDaniel e t al., 1995) , suggesting that the gene products encoded by pSY 15 are responsible for cyclizations of aromatic rings. On the basis of the ability of pSY15 to complement a S. galilaeus mutant accumulating 2-OH anthracycline metabolites, we have shown that it encodes a ketoreductase, which eliminates a hydroxyl group at C-2 of such metabolites (Ylihonko e t al., 1996) . These findings suggest that the activities needed to form the anthracycline chromophore are encoded in the 12 kb BglrI fragment from S. nogalater genomic DNA. The best-documented gene cluster for anthracyclines is that of daunomycin (Grimm et al., 1994; Ye e t al., 1994) . However, biosynthetic intermediates were obtained by heterologous expression only when large fragments were cloned since the genes for acyl carrier protein (ACP) and a transcriptional activator (dnd) are not closely linked to other minimal PKS components (Grimm e t al., 1994) .
Usually the three ORFs for minimal PI<S in aromatic polyketides (the P-ketosynthase, the chain length factor (CLF) and the acyl carrier protein; McDaniel e t al., The most significant result was the successful production of 'hybrid' anthracyclines by direct complementation of the S. galilaeus anthracycline-non-producing mutant with the plasmid pSY15. The fact that the anthracyclines produced contained a methyl side chain at C-9 suggests that the genes from S. nogalater determined the starter unit used in biosynthesis of the hybrid anthracyclines. 5'.
lividans TI<24(pSY 15) did not produce auramycinone (Fig, 1, Ill) , although it was able to produce a tricyclic intermediate of it. Therefore, it seems that the cluster in pSY15 lacks a cyclase needed to complete formation of the intact aglycone. In the S. galilaeus mutant, the corresponding enzyme is derived from the host. The stereochemistry of the aglycone formed is characteristic of the products of S. galilaeus rather than S. nogalater metabolites, whereas the side chain at C-9 is acetatederived, as in nogalamycin (Fig. 1) . On the basis of the structure of the aglycone, the hybrid compounds are related to auramycin anthracyclines.
